GH Research (FRA:1KA) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GH Research Asset Impairment Charge?

GH Research's Asset Impairment Charge for the three months ended in Mar. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

GH Research Asset Impairment Charge Historical Data

The historical data trend for GH Research's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Asset Impairment Charge Chart

GH Research Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

GH Research Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial													-	-	-	-	-

GH Research Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

GH Research Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of GH Research's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

GH Research (FRA:1KA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (FRA:1KA) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

GHRS:USA

Address

28 Baggot Street Lower, Dublin, IRL, D02 NX43

Website

https://www.ghres.com

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its focus is on developing novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

GH Research (FRA:1KA) Headlines

No Headlines